Adam Fedyk, MD
Ophthalmology · Town & Country, MONPI 1356544209
Payments from drug & device makers
Across 922 payments — averaging $655.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$417K
- AbbVie$174K
- Derma Sciences, Inc.$4K
- Mallinckrodt Hospital Products Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Bausch & Lomb Americas Inc.$1K
- plus $5K from 24 others
What the payments were for
- Consulting fees$7,27544%
- Travel & lodging$1,65210%
- Food & beverage$7,48045%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 626 | $416,547 |
| AbbVie(2 entities) | 57 | $173,634 |
| Derma Sciences, Inc. | 5 | $4,193 |
| Mallinckrodt Hospital Products Inc. | 10 | $2,405 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $1,978 |
| Bausch & Lomb Americas Inc. | 39 | $1,053 |
| Glaukos Corporation | 19 | $740 |
| Alcon | 25 | $687 |
| Sun Pharmaceutical Industries Inc. | 32 | $658 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $647 |
| NEW World Medical,inc. | 13 | $360 |
| Harrow Eye, LLC | 15 | $352 |
| Oyster Point Pharma, Inc. | 12 | $314 |
| Ocular Therapeutix, Inc. | 4 | $176 |
| Thea Pharma Inc. | 7 | $160 |
| Rxsight Inc | 1 | $138 |
| Carl Zeiss Meditec, Inc. | 1 | $110 |
| Tarsus Pharmaceuticals, Inc. | 3 | $102 |
| Amgen(2 entities) | 4 | $81 |
| Kala Pharmaceuticals, Inc. | 3 | $60 |
| Biotissue Holdings Inc. | 5 | $46 |
| Sight Sciences, Inc. | 2 | $39 |
| Novartis | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Shire North American Group Inc | 2 | $30 |
| Dompe US, Inc. | 1 | $25 |
| Kedrion Biopharma, Inc. | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIODRESTORE$4,193
- TENOGLIDE$4,193
- BIOFIX$4,193
- ACTHAR$2,250
- Tecnis 1-piece IOL$1,484
- Tecnis Multifocal Family of 1-piece IOLS$1,484
- Tecnis Symfony IOL$1,484
- RESTASIS MULTIDOSE$1,000
- Tecnis IOL$375
- STELLARIS$237
- ENVISTA$219
- Kahook Dual Blade$141
- Streamline Surgical System$141
- Ahmed Glaucoma Valve$141
- RXSIGHT INJECTOR HANDPIECE$138
- RXSIGHT CONTACT LENS$138
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$138
- LIGHT ADJUSTABLE LENS (LAL)$138
- RXSIGHT INJECTOR CARTRIDGE$138
- KXL System$133
How this compares
$604,671 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 106 | $136,173 |
| XiidraLifitegrast | 96 | $128,848 |
| LumiganBimatoprost | 110 | $64,915 |
| Cyclosporine | 34 | $27,851 |
| TyrvayaVarenicline Tartrate | 33 | $21,155 |
| Prednisolone Acetate | 523 | $20,513 |
| Lotemax SmLoteprednol Etabonate | 53 | $13,793 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,219 |
| VyzultaLatanoprostene Bunod | 20 | $8,122 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $7,315 |
| Brimonidine Tartrate | 100 | $7,210 |
| Latanoprost | 567 | $5,555 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $5,458 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $2,759 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 216 | $2,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $173,634 | $208,402229 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,053 | $148,189131 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $314 | $21,15533 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $647 | $15,95468 claims |
| AlconSimbrinza | $687 | $5,45823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Town & Country
- Nancy HolekampChesterfield$2.7M
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Steven CouchSaint Louis$1.2M
- Andrew MoyesKansas City$1.1M
- Ranjan MalhotraSaint Louis$964K
- Navin TekwaniSaint Louis$957K
- Joseph GiraDes Peres$926K
- Michael KorenfeldWashington$821K
- Gregg BerdySaint Louis$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.